![]() There is a lot of innovation happening, but it’s still largely controlled by only a couple of players,” Grand said. “Dialysis is definitely a pretty insular space. Outset’s results under Trigg’s leadership show what she’s contributed to the company and the future of dialysis treatment, MedTech Innovator CEO Paul Grand said. It’ll take a different mindset to disrupt the dialysis space, currently controlled by DaVita and Fresenius Medical Care. “Often, it is the greatest advantage to sort of have that beginner’s mindset because you will ask those sort of why and why not questions and be open to the answers that you find on your own.” “Trust your instincts,” she told the hundreds of medtech insiders in attendance for her interview with DeviceTalks Editorial Director Tom Salemi. The October 2022 event in Santa Clara was near Outset’s San Jose, California headquarters. But that worked in her favor, she said at our DeviceTalks West show. Last year, Outset had to put new shipments on hold while working through a submission review with the FDA.Īnd when she first got involved with the company, Trigg - who’s not an engineer or a doctor - didn’t know much about dialysis. For example, it increased transportation costs for its single-use cartridges made by a contract manufacturer in Southeast Asia. The pandemic also disrupted Outset’s supply chain. The COVID-19 pandemic made it unsafe to train nurses in person, even as hospitals used the Tablo hemodialysis console in hallways and waiting rooms to clean patients’ blood. Outset Medical Chair and CEO Leslie Trigg The home dialysis developer’s CEO discusses leadership, leaping before you look and making medtech for the home and hospital.Įight years after becoming the CEO of Outset Medical (Nasdaq:OM) and two years after going public, Leslie Trigg says the medtech developer is finally at the starting gate for home dialysis.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |